Refine
Has Fulltext
- yes (8)
Is part of the Bibliography
- yes (8)
Document Type
- Journal article (8)
Language
- English (8) (remove)
Keywords
- cancer (4)
- oncolytic virus (3)
- angiogenesis (2)
- breast-tumors (2)
- nude-mice (2)
- Agent (1)
- Breast-tumors (1)
- COX-2 (1)
- Cancer (1)
- In-vivo (1)
- Inhibitor (1)
- Lung cancer (1)
- Lungenkrebs (1)
- Malignant effusion (1)
- Nude-mice (1)
- Oncolytic virotherapy (1)
- Tissue (1)
- VEGF (1)
- Vascular endothelial Growth Factor (1)
- animal-model (1)
- antibodies (1)
- antibody production (1)
- boolean modeling (1)
- cancer therapy (1)
- cancer treatment (1)
- canine and feline cancer therapy (1)
- canine cancer cell lines (1)
- canine cancer therapy (1)
- canine soft tissue sarcoma (CSTS) (1)
- carcinomas (1)
- cell cultures (1)
- cell-line (1)
- dogs (1)
- endothelial growth-factor (1)
- enzyme-linked immunoassays (1)
- glv-1h68 (1)
- human xenografted mouse models (1)
- in-vitro (1)
- microenvironment (1)
- microvascular density (1)
- model (1)
- neutrophils (1)
- oncolysis (1)
- oncolytic viruses (1)
- pet dogs (1)
- therapy (1)
- vaccinia virus (1)
- viral replication (1)
- virotherapy (1)
Institute
Virotherapy on the basis of oncolytic vaccinia virus (VACV) strains is a novel approach for canine cancer therapy. Here we describe, for the first time, the characterization and the use of VACV strain GLV-5b451 expressing the anti-vascular endothelial growth factor (VEGF) single-chain antibody (scAb) GLAF-2 as therapeutic agent against different canine cancers. Cell culture data demonstrated that GLV-5b451 efficiently infected and destroyed all four tested canine cancer cell lines including: mammary carcinoma (MTH52c), mammary adenoma (ZMTH3), prostate carcinoma (CT1258), and soft tissue sarcoma (STSA-1). The GLV-5b451 virus-mediated production of GLAF-2 antibody was observed in all four cancer cell lines. In addition, this antibody specifically recognized canine VEGF. Finally, in canine soft tissue sarcoma (CSTS) xenografted mice, a single systemic administration of GLV-5b451 was found to be safe and led to anti-tumor effects resulting in the significant reduction and substantial long-term inhibition of tumor growth. A CD31-based immuno-staining showed significantly decreased neo-angiogenesis in GLV-5b451-treated tumors compared to the controls. In summary, these findings indicate that GLV-5b451 has potential for use as a therapeutic agent in the treatment of CSTS.